Merck, Inc.
A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
- Conditions
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT05130086
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
- Conditions
- Interventions
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 165
- Registration Number
- NCT05119855
- Locations
- 🇺🇸
West Houston Clinical Research Services ( Site 0078), Houston, Texas, United States
🇺🇸Next Level Urgent Care, LLC ( Site 0099), Houston, Texas, United States
🇺🇸Ark Clinical Research ( Site 0108), Tustin, California, United States
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)
- Conditions
- Interventions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 616
- Registration Number
- NCT05116189
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School-Division of Gynecologic Oncology ( Site 0003), Worcester, Massachusetts, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center ( Site 0007), Hackensack, New Jersey, United States
🇨🇦BC Cancer Victoria ( Site 0513), Victoria, British Columbia, Canada
Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT05115838
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT05093972
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
- Conditions
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6105
- Registration Number
- NCT05093933
- Locations
- 🇨🇦
G A Research Associates ( Site 0652), Moncton, New Brunswick, Canada
🇺🇸South Florida Research Solutions ( Site 0058), Hollywood, Florida, United States
🇺🇸Georgia Arrhythmia Consultants and Research Institute ( Site 0042), Macon, Georgia, United States
A Study of MK-0616 in Participants With Moderate Renal Impairment (MK-0616-007)
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT05070390
- Locations
- 🇺🇸
Alliance for Multispecialty Research, LLC ( Site 0001), Knoxville, Tennessee, United States
🇺🇸Velocity Clinical Research, Hallandale Beach ( Site 0002), Hallandale Beach, Florida, United States
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 830
- Registration Number
- NCT05067283
- Locations
- 🇺🇸
Moffitt Cancer Center ( Site 0261), Tampa, Florida, United States
🇺🇸START Midwest ( Site 0267), Grand Rapids, Michigan, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260), Hackensack, New Jersey, United States
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 505
- Registration Number
- NCT05064059
- Locations
- 🇨🇳
Fujian Province Cancer Hospital ( Site 1178), Fuzhou, Fujian, China
🇨🇳Guangxi Medical University Affiliated Tumor Hospital ( Site 1158), Nanning, Guangxi, China
🇨🇳Wuhan Union Hospital Cancer Center ( Site 1162), Wuhan, Hubei, China
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT05038800
- Locations
- 🇮🇱
Hadassah Medical Center ( Site 0100), Jerusalem, Israel
🇮🇱Sheba Medical Center-Hemato Oncology ( Site 0101), Ramat Gan, Israel
🇺🇸University of Texas MD Anderson Cancer Center ( Site 0004), Houston, Texas, United States